摘要
急性髓系白血病(AML)是一种高度异质性的恶性血液病,临床治疗以传统化疗为主,但疗效有限,部分患者因体能状态差及合并疾病而不能接受化疗。近年来,免疫治疗在AML中取得了一定的疗效,具有较好的应用前景。文章对第60届美国血液学会(ASH)年会报道的AML免疫治疗新进展进行综述。
Acute myelogenous leukemia(AML)is a highly heterogeneous malignant hematologic disease,and its clinical treatment mainly includes traditional chemotherapy,but the efficacy is limited and the patients with worse performance status and comorbidities can not be treated with chemotherapy.In recent years,immunotherapy has achieved certain curative effects in AML which shows a promising prospect.This review introduces immunotherapy of AML reported in 60th American Society of Hematology(ASH)Annual Meeting.
作者
米瑞华
袁芳芳
魏旭东
Mi Ruihua;Yuan Fangfang;Wei Xudong(Department of Hematology,the Affiliated Cancer Hospital of Zhengzhou University,Henan Cancer Hospital,Zhengzhou 450003,China)
出处
《白血病．淋巴瘤》
CAS
2019年第1期12-16,共5页
Journal of Leukemia & Lymphoma
基金
河南省医学科技攻关计划省部共建项目(201701027).
关键词
白血病
髓系
急性
免疫疗法
Leukemia,myelogenous,acute
Immunotherapy
